View the Preliminary Program
Take a look at the innovative lineup of topics and presenters on the FOCIS 2018 preliminary program. Additional presenters and topics will be announced as they are confirmed, so stay tuned!
Submit an Abstract
Submit your science to FOCIS 2018! Share your findings in front of leading clinicians and researchers in immunology. Abstracts are presented during Thematic Symposia, Oral Abstract Sessions, and at the evening Poster Sessions.
Register today for THE meeting that will give you a competitive edge in your career. FOCIS registration includes more than 20 scientific sessions with more than 50 top clinicians and researchers from around the globe, speaking on cutting-edge topics across immunology and its related fields.
Book Your Hotel Room
FOCIS 2018 will be held at the San Francisco Marriott Marquis, located downtown in the South of Market (SoMa) neighborhood. Stay where all the action is! FOCIS has negotiated a special rate for FOCIS delegates of $304/night. Discounted trainee rooms are available for $209/night. Book your room today!
See you in San Francisco! #FOCIS
The Entrepreneurs in Clinical Academia (ECA) 2017 course took place at the INSEAD campus in Fontainebleau, France, on 16-20 October. This is the 5th year in a row that the course has taken place. ECA is an initiative from FOCIS which offers to a small selected group of academic researchers involved in immunology or inflammatory research in Europe the opportunity to discover more about the drug development process and how to get the most out of their research. The course is delivered by INSEAD, one of the best and largest international business schools whose MBA program is ranked the #1 program in the world by the Financial Times. ECA is a free course. All course expenses are covered by FOCIS, thanks to generous support from Celgene. ECA is a powerful and inspiring course during which participants learn what it takes to move a molecule from the laboratory to the market. At the end of the course they understand the importance of obtaining intellectual property, how to assess its economic value, know what data they must generate to satisfy regulators and other stakeholders, the financial resources and skills required to generate these data, and how venture capital companies, biopharmaceutical companies, their university technology transfer office and other parties can help academic entrepreneurs achieve their goals.
To introduce our membership to Dr. Anegon, we interviewed him about his career path, proudest achievements, his current work at INSERM in Paris, France, and why he chose to lead the Multinational FCEs. Listen to the full interview or read the transcription below.
1. What attracted you to the field of immunology?
I became attracted to immunology early on when I was a medical student in the early 1980's. At that time, it was a very complex and fascinating system with different cells. There weren't as many cells as there are now, but there were already several different types and they weren't very well known. It was challenging, but intellectually it was very stimulating. I could also see clearly that the new system had an impact not only the diseases of the immune system itself, but also on other diseases that were not necessarily immune in their origin but in which the immune response was also playing a role. It was very broad.
2. After you received your medical degree from Universidad de la Républica del Uruguay, how did you decide to do your postdoctoral work at the University Hospital of Barcelona?
At the time, research was difficult in Uruguay because of political and economic climate. Also, international contacts were scarce. At that time, there was no internet or email, from Latin America few people would get in contact with colleagues in other countries. I did have one Dr. Jordi Vives, a researcher who led the best (at that time) immunology lab located in Barcelona. The lab was beginning to generate monocolonal antibodies to define immune cells. I wanted to learn that technology and that application and that's why I chose to join his lab. This was a good move, as I ran the first cytofluorumeter spectrometer in Spain, and I participated in the first international workshop to define CD leukocyte antigens. That was the beginning of what we know nowadays - that we hundreds of these CD markers. That workshop was in Boston, Massachusetts, and was the first in the world. It was new and cutting-edge at the time.
3. You then moved to the University of Pennsylvania to become an Associate Scientist at the Wistar Institute. What motivated you to make this move?
I thought it was important to have an experience in an American University. I also wanted to learn more immunology and molecular biology (which was becoming essential). When I went to work at the Wister Institute at the University of Pennsylvania, it was a very good place. I had the chance of working with human NK cells, Fc gamma receptors, and I also learned molecular biology techniques that we applied to human immune cells. All this was new and exciting. I had a very good boss at the time, Bice Perussia, who was associated with Giorgio Trinchieri. They were excellent scientists with very good labs.
4. In 1988, you moved to Nantes, France to become the visiting scientist at the Institut National de la Santé Et de la Recherche Médicale INSERM, and then received a permanent position. What are some of your proudest moments since you've been working there?
I am proud of the career that I've had at INSERM – and all of it has been through competitive examinations. All the positions were given by scientific committees who are nationally-based and independent - with no politics. The focus of the examination is on the quality of the candidate and the quality of the project.
Now I have the highest position in the French research system, which is a source of pride for me.
I also like that I have initiated areas and topics of research that were not previously covered at Nantes – and in some cases not even in France. I initiated the generation of genetically modified rats; and I created an open facility that works with many groups in France and abroad (in both academia and industry). This area of my work is very active since because we have incorporated many new technologies, for example genome editing using zinc nucleases, TALENs (Transcription activator-like effector nucleases), CRISPR (clustered, regularly interspaced, short, palindromic repeats), we were the first ones to generate knockout rats using ZFNs and TALENs.
I also initiated work on application of gene therapy techniques in organ transplantation, which was new at that time and I was for several years editor-in- chief of an international journal in this area, Current Gene Therapy.
I also initiated work on CD8 Tregs which are less known as compared to CD4 Tregs, and this originated many publications and patents. We are now also creating a company based on this research.
Finally, I have organized and led many scientific meetings in the area of immunology and transgenesis.
I directed a large INSERM research center that has grown to 170 people in nine years, and continues to grow even now. The center was bigger and stronger when I left compared to when I took over.
I think that promoting young researchers is important and I have done this with those that have worked with me during the years and some of them have been successful scientists with whom I keep working.
Finally, our center was recognized by FOCIS as a FOCIS Center of Excellence and my work in FOCIS is also source of satisfaction.
5. You are now the Director of Research at the INSERM and scientific director of the Nantes Rat Transgenesis platform, you were Director of the INSERM unit 1064, and the Editor-in-chief of the journal Current Gene Therapy. Do you miss anything from the earlier part of your career?
Performing experiments was exciting but difficult also. I remember the excitement of seeing the results coming out of machines. I still always see the scientific results not as immediately as before, but when students or fellows bring the results to the meetings, but I still always get very excited when I see them, so I still have that joy.
And what I also enjoy now), is having the possibility of imagining the hypotheses, projects and experiments. This is something you do less of when you are young and performing the experiments.
And I also think that organizing research within a larger vision is also very exciting and interesting. For example, now I'm the head of the network of immunology laboratories located in the north of France, and they have significant funding. I like to create new technologies or platforms, or programs for funding students, or for defining new areas of research.
6. Looking back on your career, is there anything you would have done differently?
I took very important and significant decisions based on my career, like for example leaving my country of origin. But at same time, I did not always make decisions in my life that were necessarily work-based. I also took into considerations other things like quality of life, family, the kind of country/society in which I wanted to live. I would do the same thing again. For younger people, it's important to follow our own professional obligations and motivations of course, but at the same time to put a limit to it. I think you must put into consideration of other things – not only work.
7. Switching gears, how did you first get involved with FOCIS?
Well, first I went to some FOCIS meetings because they were scientifically interesting. I went to the first one, which was in Paris, and I liked then the kind of meeting with lots of translational research. I also got involved with FOCIS because friends whom were and are very important scientists - like Jeff Bluestone, or Matthias von Herrath were already involved with FOCIS.
Then, I became the director of our research center and I thought about [our center] becoming an FCE which would be good for us, because we were already doing basic translational and clinical research that FOCIS was promoting. But at that time, it was more restricted to transplant immunology. Nowadays, we have in the Nantes FCE a much larger immunology community, with autoimmunity and cancer. Later, Abul Abbas invited me to become the FOCIS Multi-national FCE Chair, and I was very happy with this also.
8. How has FOCIS changed your world?
Well, the FOCIS meetings are excellent scientifically and opened my mind to other experimental models and pathologies. I have integrated different immunology specialties in my work, like autoimmunity, that I've learned and have come to appreciate through FOCIS. Many great scientists go to FOCIS meetings and I have also incorporated some these contacts in my world.,
9. What are some of your biggest accomplishments as FOCIS Multinational FCE Chair?
I've promoted the creation of new FCE's in Europe and in Latin America, so I'm happy with that because that was one of my goals. And there are several new FCE's in the last couple of years. Also, I like the idea [and it's been successful] of creating FOCIS courses and meetings in Europe and Latin America, and that's how we generated the first FOCIS course on basic and translational immunology in Europe in 2016. And now in 2017, there is the second one, and there will be European courses in 2018 and 2019. And this year, we held the first FOCIS course and meeting in Latin America (in Chile), and it was successful. And we are going to have a new FOCIS event in Latin America (in Cancun, Mexico) next year during the Meeting of the Latin American Association for Immunology, so that's something that I'm happy about.
10. What are your future goals as the FOCIS Multinational FCE Chair?
I would like to develop these kinds of activities in Europe and Latin American, and I think it would be great if we could do it in Asia, and eventually in other regions. We already have plans to hold a course in India in early 2019.
11. If your colleague asked you why they should join FOCIS, what would you tell them?
The FOCIS meetings are very good – they have excellent science. They are also a very good opportunity for networking - there are excellent scientists going there and there is plenty of time during the meeting also to do this. FOCIS organizes multiple opportunities for FOCIS members and FCEs to get together. I think the FCEs are also an interesting aspect of FOCIS. The courses that FOCIS organizes are excellent, and that's another reason that distinguishes FOCIS from other academic societies.
12. Do you have any advice to share with someone who is just starting out in the field?
I would say, first, be original in your research, do things that have not been done - that's essential. And then always stay updated and on the cutting-edge of new technologies, and join FOCIS!
13. What motivates you to work hard?
Intellectual curiosity I would say, and the interactions with young people - it's also very interesting and very motivating.
14. What is your favorite time management tool?
I'm kind of old school– I have a paper agenda in a big format with big pages in which I can write all my meetings and appointments and these kinds of things.
15. What is a favorite vacation spot?
There is a place far away in Uruguay called Cabo Polonio. It's a small fisherman town on the seaside –isolated, very beautiful and the nature is great. I enjoy going there with family and friends and I try to go every year... I'm going this year also, and looking to that.
16. What is your favorite beverage or drink?
Red wine - I love the southwest wines in France and also the Latin American ones - like Chilean, Argentinians, Uruguayans red wines.
Dr. Ignacio Anegon was born in Uruguay August 29th, 1956. He received his Medical Doctor degree from the Universidad de la Républica del Uruguay in 1982. Between 1979 and 1982, he worked in clinical immunology in the University Hospital. Ignacio ANEGON did his postdoctoral work in the Immunology Department of the University Hospital of Barcelona between 1982 and 1985. His research was on the generation and characterization of monoclonal antibodies against human leukocytes as well as application of cytofluorimetry and monoclonal antibodies for typing human leukemias and lymphomas. Between 1985 and 1988, he was Associate Scientist at the Wistar Institute University of Pennsylvania. His area of research was on CD16 receptors and human NK cell biology with the use of cellular and molecular biology techniques. In 1988, he was a visiting scientist at the Institut National de la Santé Et de la Recherche Médicale INSERM in Nantes France. In 1989, he obtained a permanent position at the INSERM. Since he has been working in France, his research focused in transplantation immunology - mainly immunoregulation by dendritic cells and by CD8 Tregs and in Functional Genomics mainly transfer using viral vectors and the generation of transgenic and knockout rats. He is now Director of Research at the INSERM and was Director of the INSERM unit 643/1064 (2009 and 2017) and he is now director of a team in this INSERM unit, director of the Nantes Rat Transgenesis platform and of a network of regional immunology laboratories (the Labex Immunology Graft Oncology). He has published more than 220 papers, edited 3 books and was Editor-in-chief of the journal Current Gene Therapy (2014-2017) and is now Deputy editor of Transplantation. He has been Chair of the Multinational FOCIS Centers of Excellence since 2015.
Research interests: Transplantation immunology, immunoregulatory cells (Dendritic cells, CD8+ Tregs), gene transfer using viral vectors and generation of transgenic animals
FCE and regional researchers brought together in Santiago de Chile during May 15th-17th to present current scenarios and challenges in immunology. The Workshop "FOCIS goes South: Advances in Translational and Clinical Immunology" was organized by the FCE Millennium Institute on Immunology and Immunotherapy at the Pontificia Universidad Católica de Chile and gathered scientists from USA, France, Argentina, Brazil, Chile, Uruguay and Mexico, among others.
The inauguration ceremony of the Workshop was presided by the President of the Pontificia Universidad Católica de Chile, Dr. Ignacio Sánchez, the Minister of Economy, Natalia Piergentili, Senator Guido Girardi, the Director of Energy, Science, Technology and Innovation at the Ministry of Foreign Affairs, Ambassador Gabriel Rodríguez, FOCIS Multi-national FCE Chair, Dr.Ignacio Anegon, the Director of the Millennium Institute on Immunology and Immunotherapy (MIII), Dr. Alexis Kalergis, Associate Researcher at MIII and one of the organizers of the Meeting, Dr. Pablo González.
The Lupus Research Alliance has two open opportunities for significant funding for lupus research and for notable recognition of a scientific breakthrough of relevance to lupus.
Request for Applications for the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity ($1 million over four years). This grant mechanism is intended to attract exceptionally creative scientists from all relevant scientific disciplines and to provide them with a robust and sustained support to explore bold and paradigm shifting ideas that could lead to ground-breaking discoveries in lupus research. Investigators working in areas outside of lupus are strongly encouraged to apply. The Lupus Research Alliance welcomes novel, hypothesis- or discovery-driven proposals in human and/or animal-model based lupus research. The research proposal must aim to uncover the fundamental causes of lupus and present a compelling vision of how the discovery would lay the groundwork for a cure, prevention, or highly effective therapy. Applications will be judged primarily on the novelty and potential of the research proposal, and the strengths and track record of the investigator. Emphasis will be on the rationale for the hypothesis rather than the amount of preliminary data. Successful applicants will be outstanding investigators who have demonstrated creativity and productivity in their field of research. We encourage applications from investigators in diverse disciplines including, but not limited to, immunology, genetics, molecular-, cell- and systems biology.
Applicants must hold a faculty position, at the assistant professor level or above, at an academicinstitution in or outside of the US.
A 2-page Letter of Intent (LOI) will be used to judge the significance, novelty and alignment of the proposed project concept with the funding mechanism. Applicants of successful LOIs will be invited to submit full applications. The LOI deadline is March 5, 2018. For further information, please click here.
Call for Nominations for the 2018 Lupus Insight Prize. The $100,000 Prize recognizes significant scientific insights relevant to understanding the causes, biology, or treatment of lupus. While the insight need not have been made specifically about lupus, it should be applicable and applied, using the Prize funds, to understanding lupus pathogenesis or informing lupus treatment. The Prize aims to stimulate further advances leading to improved outcomes for patients with lupus and ultimately to a cure.
The primary objective of the Lupus Insight Prize is to identify and recognize an outstanding investigator who has developed a novel research insight in scientific domains relevant to lupus. The Prize is not a lifetime achievement award. The Lupus Insight Prize will be awarded to an outstanding investigator with a documented record of creativity, innovation, and productivity who has made a novel insight and/or discovery in an area of research that is applicable to the pathogenesis or treatment of lupus and who is judged to have a high likelihood of generating further significant advances by applying the insight to lupus. This should shift the current paradigms and should significantly advance lupus understanding or treatment.
The nomination deadline is February 15, 2018. For further information, please visit http://lupusinsightprize.org.